| 4.955 -0.205 (-3.97%) | 09-23 10:42 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.66 | 1-year : | 8.25 |
| Resists | First : | 5.71 | Second : | 7.07 |
| Pivot price | 5.26 |
|||
| Supports | First : | 3.5 | Second : | 2.92 |
| MAs | MA(5) : | 5.17 |
MA(20) : | 4.88 |
| MA(100) : | 4.2 |
MA(250) : | 3.51 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 43 |
D(3) : | 46 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 7.07 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IRD ] has closed above bottom band by 39.1%. Bollinger Bands are 86% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.31 - 5.34 | 5.34 - 5.37 |
| Low: | 4.95 - 4.99 | 4.99 - 5.02 |
| Close: | 5.1 - 5.16 | 5.16 - 5.21 |
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Sat, 19 Sep 2026
IRD Should I Buy - Intellectia AI
Wed, 16 Sep 2026
Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified? - Yahoo Finance
Thu, 10 Sep 2026
Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD) - Seeking Alpha
Wed, 09 Sep 2026
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial - tradingview.com
Wed, 09 Sep 2026
IRD Stock Eyes Webcast Catalyst As Gene Therapy Data Nears - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -39 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 8.32e+007 (%) |
| Held by Institutions | 6.521e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.877e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.29 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 182.7 % |
| Return on Equity (ttm) | -48.1 % |
| Qtrly Rev. Growth | 796.5 % |
| Gross Profit (p.s.) | -90.36 |
| Sales Per Share | 1061.78 |
| EBITDA (p.s.) | -3.83036e+007 |
| Qtrly Earnings Growth | -5.055e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -3.9 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 1.125e+007 |
| Forward Dividend | 1.027e+007 |
| Dividend Yield | 224104000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|